- cafead Jan 12, 2022 at 11:32: AM
via Is there a good reason to split one drug into multiple brands?
Plenty of drugmakers have already made this decision, including Novo Nordisk with its Wegovy and Ozempic GLP-1 drugs. Now, Eli Lilly CEO Dave Ricks is weighing the idea with its blockbuster-in-waiting, tirzepatide.
article source
Plenty of drugmakers have already made this decision, including Novo Nordisk with its Wegovy and Ozempic GLP-1 drugs. Now, Eli Lilly CEO Dave Ricks is weighing the idea with its blockbuster-in-waiting, tirzepatide.
article source